Phase I/Ib Clinical Trial of Sabatolimab, an Anti‐TIM‐3 Antibody, Alone and in Combination with Spartalizumab, an Anti‐PD‐1 Antibody, in Advanced Solid Tumors
Open accessPublished version of a preprint
The DOI matches its Crossref record; 38 of the 41 references it cites were found in a registry or an index.
Abstract
Abstract Purpose: Sabatolimab (MBG453) and spartalizumab are mAbs that bind T-cell immunoglobulin domain and mucin domain-3 (TIM-3) and programmed death-1 (PD-1), respectively. This phase I/II study evaluated the safety and efficacy of sabatolimab, with or without spartalizumab, in patients with advanced solid tumors. Patients and Methods: Primary objectives of the phase I/Ib part were to characterize the safety and estimate recommended phase II dose (RP2D) for future studies. Dose escalation was guided by a Bayesian (hierarchical) logistic regression model. Sabatolimab was administered intravenously, 20 to 1,200 mg, every 2 or 4 weeks (Q2W or Q4W). Spartalizumab was administered intravenously, 80 to 400 mg, Q2W or Q4W. Results: Enrolled patients (n = 219) had a range of cancers, most commonly ovarian (17%) and colorectal cancer (7%); patients received sabatolimab (n = 133) or sabatolimab plus spartalizumab (n = 86). The MTD was not reached. The most common adverse event suspected to be treatment-related was fatigue (9%, sabatolimab; 15%, combination). No responses were seen with sabatolimab. Five patients receiving combination treatment had partial responses (6%; lasting 12–27 months) in colorectal cancer (n = 2), non–small cell lung cancer (NSCLC), malignant perianal melanoma, and SCLC. Of the five, two patients had elevated expression of immune markers in baseline biopsies; another three had >10% TIM-3–positive staining, including one patient with NSCLC who received prior PD-1 therapy. Conclusions: Sabatolimab plus spartalizumab was well tolerated and showed preliminary signs of antitumor activity. The RP2D for sabatolimab was selected as 800 mg Q4W (alternatively Q3W or Q2W schedules, based on modeling), with or without 400 mg spartalizumab Q4W.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The results of clinical trials showed that α-TIM-3 plus α-PD-1/PD-L1 was tolerable without unexpected safety signals, but more efforts are needed for patient selection [158–160].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [160]
In the citing paper
“Several ongoing clinical trials investigating the blockade of TIM‐3 inhibitor (sabatolimab) with or without PD‐1 inhibitors in advanced solid tumors concluded that the doses for combination therapy of sabatolimab and spartalizumab were under tolerance and showed anti‐cancer activity with survival benefits [349].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [349]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“Immunotherapy is an important treatment strategy in cancer (1,2); however, many”
BackgroundIFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 2×
“In animal models, dual blockade of TIM-3 and PD-1 restored T-cell function and suppressed tumor growth more effectively than targeting either pathway alone, supporting a rationale for combination therapy (7, 10).”
BackgroundFraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785 · cited 1×
“Tumor biopsies were also analyzed using RNA sequencing (24,25); analyses focused on 28 genes and 7 gene signatures related to immune cell infiltration/function or pathways associated with TIM-3.”
MethodKoyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580 · cited 2×
“observation that TIM-3 upregulation has been seen following progression on PD-1 treatment (8).”
BackgroundSelf-citationFourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307 · cited 1×
“It is broadly expressed on myeloid cells, natural killer cells, and dysfunctional T cells, often co-expressed with PD-1 (5-7).”
BackgroundGong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,273 · cited 1×
“Immunotherapy is an important treatment strategy in cancer (1, 2); however, many patients still fail to respond to checkpoint inhibitors or progress on treatment, highlighting a need for novel therapies and combinations (1, 3).”
BackgroundCancer phase I clinical trials: efficient dose escalation with overdose control
Babb, J., Rogatko, A., & Zacks, S. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980530)17:10<1103::aid-sim793>3.0.co;2-9 · Cited by 623 · cited 1×
“regression model (19) following the escalation with overdose control (EWOC) principle (20).”
BackgroundGenetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Orlando, E. J., Han, X., Tribouley, C., Wood, P. A., Leary, R. J., Riester, M., Levine, J. E., Qayed, M., Grupp, S. A., Boyer, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0146-z · Cited by 575 · cited 1×
“Tumor biopsies were also analyzed using RNA sequencing (24, 25); analyses focused on 28 genes and 7 gene signatures related to immune cell infiltration/function or pathways associated with TIM-3.”
Method
Research works printed but not linked: 1
- Davar D, Boasberg P, Eroglu Z, Falchook G, Gainor J, Hamilton E, et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma. J Immunother Cancer 2018;6:O21.
Cited by
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
“The antitumour response of sabatolimab (MBG453), a mAb that inhibits TIM-3 checkpoint, has been observed in phase 1/2 clinical trials.(61) A randomized, double-blind, placebocontrolled phase 3 study of MBG453 is currently active in 530 patients with myelodysplastic or chronic myelomonocytic leukaemia-2 (NCT04266301).”
BackgroundImmunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Cai, L., Li, Y., Tan, J., Xu, L., & Li, Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01499-1 · Cited by 391
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
“While no response was seen with sabatolimab in advanced solid tumor including melanoma, patients undergoing the treatment of sabatolimab plus PD-1 antibody exhibit better response signs like elevated expression of immune markers.(641,642) LY3321367 has demonstrated promising antitumor activity in single use or in comb…”
Background
Metadata
- Authors
- Curigliano, G., Gelderblom, H., Mach, N., Doi, T., Tai, D., Forde, P. M., Sarantopoulos, J., Bedard, P. L., Lin, C.-C., Hodi, F. S., Wilgenhof, S., Santoro, A., Sabatos-Peyton, C. A., Longmire, T. A., Xyrafas, A., Sun, H., Gutzwiller, S., Manenti, L., & Naing, A.
- Affiliations
- University of Milan (IT)
- Leiden University Medical Center (NL)
- University Hospital of Geneva (CH)
- National Cancer Center Hospital East (JP)
- National Cancer Centre Singapore (SG)
- Johns Hopkins University (US)
- The University of Texas at San Antonio Health Science Center (US)
- Princess Margaret Cancer Centre (CA)
- National Taiwan University Hospital (TW)
- Dana-Farber Cancer Institute (US)
- The Netherlands Cancer Institute (NL)
- Humanitas University (IT)
- Novartis (Switzerland) (CH)
- 15Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Curigliano, Giuseppe
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2021-04-21
- Volume
- 27
- Issue
- 13
- Pages
- 3620-3629
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W3156148127
- Cited by
- 362
- References
- 41
- Citations by year
- 2026: 46 · 2025: 87 · 2024: 82 · 2023: 84 · 2022: 54 · 2021: 9
- FWCI
- 21.04
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-09-03)
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Novartis Pharmaceuticals Corporation (P30CA054174)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- spartalizumab, TIM-3, PD-1, anti-PD-1, anti-TIM-3 antibody, combination immunotherapy, advanced solid tumors, ovarian cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, melanoma, dose escalation, recommended phase 2 dose
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Drug Combinations, Female, Humans, Male, Middle Aged, Neoplasm Staging, Neoplasms, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I/Ib Clinical Trial of Sabatolimab, an Anti‐TIM‐3 Antibody, Alone and in Combination with Spartalizumab, an Anti‐PD‐1 Antibody, in Advanced Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-4746
- The paper
- Curigliano, G., Gelderblom, H., Mach, N., Doi, T., Tai, D., Forde, P. M., Sarantopoulos, J., Bedard, P. L., Lin, C.-C., Hodi, F. S., Wilgenhof, S., Santoro, A., Sabatos-Peyton, C. A., Longmire, T. A., Xyrafas, A., Sun, H., Gutzwiller, S., Manenti, L., & Naing, A. (2021). Phase I/Ib Clinical Trial of Sabatolimab, an Anti‐TIM‐3 Antibody, Alone and in Combination with Spartalizumab, an Anti‐PD‐1 Antibody, in Advanced Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-4746
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.